Pharmacotherapy in personality disorders

Journal of Psychosocial Nursing and Mental Health Services

Volumn 45, Issue 6, 2007, Pages 15-19

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547272585     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20070601-06     Document Type: Review

References (39)

1. th ed.). Washington, DC: Author.
2. Aschauer, H.N., & Schlogelhofer, M. (2005). Anxiety, depression, and personality. In S. Kasper, J.A. den Boer, &. J.M. Ad Sitsen (Eds.), Handbook of depression and anxiety: A biological approach, second edition (pp. 91-110). New York: Marcel Dekker.
3. Barbee, J.G., Conrad, E.J., & Jamhour, N.J. (2004). The effectiveness of olanzapine, risperidone, quetiapine, und ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry, 65, 975-981.
4. Beck, A.T., & Freeman, A. (1990). Cognitive therapy of personality disorders. New York: Guilford Press.
5. Bond, A.J. (2001). Neurotransmitters, temperament and social functioning. European Neuropsychopharmacology, 11, 261-274.
6. Bouchard, T.J., Jr., & Loehlin, J.C. (2001). Genes, evolution, and personality. Behavior Genetics, 31, 243-273.
7. Buck, R. (1999). The biological affects: A typology. Psychological Review, 106, 501-336.
8. Caspi, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Harrington, H., et al. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301, 386-389.
9. Cloninger, C.R. (1999). A new conceptual paradigm from genetics and psychobiology for the science of mental health. Australian and New Zealand Journal of Psychiatry, 33, 174-186.
10. Cloninger, C.R., Svrakic, D.M., & Przybeck, T.R. (1993). A psychobiological mcxiel of temperament and character. Archiva of General Psychiatry, 50, 975-990.
11. Denenberg, V.H. (2000). Evolution proposes and ontogeny disposes. Brain and Language, 73, 274-296.
12. Durbin, C.E., Klein, D.N., & Schwanz, J.E. (2000). Predicting the 2 1/2-year outcome of dysthymic disorder: The roles of childhood adversity and family history of psychopathology. Journal of Consulting and Clinical Psychology, 68, 57-63.
13. Eley, T.C., & Plomin, R. (1997). Genetic analyses of emotionality. Current Opinion in Neurobiologe 7, 279-284.
14. Goodwin, F.K., Fireman, B., Simon, G.E., Hunkeler, E.M., Lee, J., & Revicki, D. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. Journal of the American Medical Association, 290, 1467-1473.
15. Grossman, R. (2002). Psychopharmacologic treatment of patients with borderline personality disorder. Psychiatric Annals, 32, 357-370.
16. Guzzetta, F., Tondo, L., Centorrino, F., & Baldessarini, R.J. (2007). Lithium treatment reduces suicide risk in recurrent major depressive disorder. Journal of Clinical Psychiatry, 68, 380-383.
17. nd ed., pp. 185-194). New York Guilford Press.
18. Howland, R.H. (2006). Personalized drug therapy with pharmacogenetics - Part 2: Pharmacodynamics. Journal of Psychosocial Nursing and Mental Health Services, 44(2), 13-16.
19. nd ed., pp. 157-185). Washington, DC: American Psychiatric Publishing.
20. nd ed., pp. 3-18). Washington, DC: American Psychiatric Publishing.
21. Kendler, K.S. (2001). Twin studies of psychiatric illness: An update. Archives of General Psychiatry, 58, 1005-1014.
22. Kiesler, D.J. (1996). Contemporary interpersonal theory and research: Personality, psychopathology, and psychotherapy. New York: Wiley and Sons.
23. Lesch, K.P., Greenberg, B.D., Higley, J.D., Bennett, A., & Murphy, D.L. (2002). Serotonin transporter, personality, and behavior: Toward a dissection of gene-gene and gene-environment interaction. In J. Benjamin & R.P. Ebstein (Eds.), Molecular genetics and the human personality (pp. 109-135). Washington, DC: American Psychiatric Publishing.
24. Links, P.S., Steiner, M., Boiago, I., & Irwin, D. (1990). Lithium therapy for borderline patients: Preliminary findings. Journal of Personality Disorders, 4, 173-181.
25. Markovitz, P.J. (2004). Recent trends in the pharmacotherapy of personality disorders. Journal of Personality Disorders, 18, 99-101.
26. McGue, M., & Bouchard, T.J. (1998). Genetic and environmental influences on human behavioral differences. Annual Review of Neurascience, 21, 1-24.
27. Melke, J. (2003). Serotonin transporter gene polymorphisms and mental health. Current Opinion in Psychiatry, 16, 215-220.
28. Morana, H.C.P., & Camara, F.P. (2006). International guidelines for the management of personality disorders. Current Opinion in Psychiatry, 19, 539-543.
29. Murphy, D.L., Li, Q., Engel, S., Wichems, C., Andrews, A., Lesch, K.P., et al. (2001). Genetic perspectives on the serotonin transporter. Brom Research Bulletin, 56, 487-494.
30. nd ed., pp. 19-42). Washington, DC: American Psychiatric Publishing.
31. Ozkaragoz, T., & Noble, E.P. (2000). Extraversion: Interaction between D2 dopamine receptor polymorphisms and parental alcoholism. Alcohol, 22, 139-146.
32. Pinto, O.C., & Akiskal, H.S. (1998). Lamotrigine as a promising approach to borderline personality: An open series without concurrent DSM-IV major mood disorder. Journal of Affective Disorders, 51, 333-343.
33. Rivas-Vazquez, R.A., & Blais, M.A. (2002). Pharmacologic treatment of personality disorders. Professional Psychology, Research and Practice, 33, 104-107.
34. Rose, S. (2001). Moving on from old dichotomies: Beyond nature-nurture towards a lifetime perspective. British Journal of Psychiatry, 178(Suppl. 40), S3-S7.
35. Rothschild, A.J., Samson, J.A., Besserte, M.P., & Carter-Campbell, J.T. (1993). Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. Journal of Clinical Psychiatry, 54, 338-342.
36. Soloff, P.H. (2000). Psychopharmacology of borderline personality disorder. Psychiatric Clinics of North America, 23, 169-192.
37. Tohen, M., Vieta, E., Calabrese, J., Ketter, T.A., Sachs, G., Bowden, C., et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry, 60, 1079-1088.
38. Townsend, M.H., Cambre, K.M., & Barbee, J.G. (2001). Treatment of border-line personality disorder with mood instability with divalproex sodium: Series of ten cases. Journal of Clinical Psychopharmacology, 21, 249-251.
39. Zanarini, M.C., Frankenburg, F.R., & Parachini, E.A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907.